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A B S T R A C T
The aim of our study is to evaluate the temporal trend of deaths in a cohort of i.v. drug users (IVDU) followed in a city
of Northen Italy (Bologna), and to assess its relationship with HIV infection and AIDS, and availability of potent anti-
retroviral therapy. One thousand and 214 IVDUs (mainly heroin addicts), 916 males and 298 females, attending an out-
patient service for treatment and prevention of substance abuse between 1977 and November 1996, were enrolled into our
observational cohort, and their vital status was ascertained up to December 31, 2002. The large majority of enrolled sub-
jects were born in the Bologna metropolitan area and surroundings; no extra-European immigrants were present. Dur-
ing the observation period, 271 IVDUs (22.3%) died, 211 males (23.0%), and 60 females (20.1%). No death was recorded
before 1984. Main death causes result as follows: AIDS (52.8% of episodes), heroin overdose (22.1%), street accidents
(7.4%), decompensated liver cirrhosis (6.3%), and suicide (2.9%). The highest absolute number of deaths was observed
between years 1991 and 1996. Crude mortality rate caused by AIDS was 10.0 per 1000 for males and 13.2/1000 for fe-
males; the rate of death due to other causes proved 11.1/1000 among males and 5.2/1000 among females. In most recent
years, a sharp decrease in the number of AIDS-related deaths, attributable to the increased use of potent antiretroviral
regimens, was recorded among IVDUs, although overall mortality rate remained appreciable.
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Introduction
A remarkable decrease of HIV-associated disorders, as
well as of notified cases of AIDS, has been observed in in-
dustrialized countries during the last seven years. Such
significant drop of HIV-related morbidity and mortality
(mostly occurred thanks to the introduction and diffu-
sion of highly active antiretroviral therapy, or HAART),
was also observed among i.v. drug users (IVDUs)1–3.
However, a significant number of potential Italian pa-
tients, still unaware of their HIV serostatus4, do not yet
make use of antiretroviral treatment: in our previously
reported series regarding the year 1997, 29% of active or
prior IVDUs were never tested for HIV infection5.
A European multicentre study6 shows how IVDUs
with recent HIV seroconversion are subject to an in-
creased risk of mortality due to pneumonia, endocarditis,
sepsis, meningitis, encephalitis, and decompensated liver
cirrhosis. Before the availability of HAART, an increased
rate of mortality due to heroin overdose and suicide was
also recorded among HIV-infected IVDUs7,8. Just the use
of elevated heroin dosages associated to a suicidal behav-
ior could be partially responsible for this phenomenon in
patients with a newly diagnosed HIV disease and lacking
of any social and psychological support, especially before
the introduction of effective antiretroviral drug combina-
tions (HAART)9–11.
In a cohort study of 4,962 IVDUs carried out in Bolo-
gna (Italy) between years 1980 and 1990, 332 deaths
were observed: 150 of them occurred because of AIDS, 64
of drug overdose, and 39 of accidents8. The HIV infection
serostatus (28.2% of 1214 subjects were positive) proved
to be significantly related also to deaths caused by trau-
ma, heroin overdose, bacterial infections, and acute and
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chronic liver disease. The mortality rate of IVDUs proved
significantly higher among those subjects who did not re-
ceive a HIV serodiagnosis with respect to those subjects
who underwent a HIV infection test with negative result
(12.1% versus 2.5%)8. Again in Bologna, at the end of
nineties the risk of a fatal heroin overdose remained re-
markably important12, while between years 1996 and
1998 Italian national cumulative data showed a progres-
sive decrease of deaths due to this last cause13.
In a cohort of 11,432 IVDUs enrolled in Rome (Italy)
between years 1980 and 1995, 1,734 deaths were regis-
tered (15.2%). The peak of AIDS-associated mortality
was observed in 1991 and 1992 (13.2 per 1000 person-
years), followed by a decrease occurred in both male and
female population since 1993–1994, even earlier than ex-
pected according to the availability of (before HAART be-
came available in mid-1996)14.
In the Emilia-Romagna region of Italy (of which Bolo-
gna is the main administrative centre and largest town),
a retrospective study conducted on 4,260 IVDUs followed
in Piacenza, Modena and Ferrara during two decades
(1975–1995), pointed out a dramatic increase in the rate
of deaths caused not only by AIDS; but also by overdose
and other causes, especially accidents. The mortality rate
observed in this last IVDUs cohort proved particularly
high: the calculated standard mortality rate (SMR) was
16.7 for males, and 33.4 for females. The overall proba-
bility of survival after 15 years of follow-up was 65%. Af-
ter drug overdose and AIDS, the other relevant causes of
deaths were street accidents, decompensated liver dis-
ease, other infectious disorders and malignancies among
male IVDUs, while accidents (in particular, homicide),
and gastrointestinal tract disorders had a greater preva-
lence among females15.
Finally, in an Italian multicentre study carried out in
Turin, Rome, Naples, and Cagliari on IVDUs enrolled be-
tween 1980 and 1992, a highly variable mortality rate
was detected, ranging from 11.0 per 1000 persons-years
in Naples, up to 20.5 per 1000 persons-years in Rome.
Again, the most frequent causes of death were repre-
sented by drug overdose, AIDS, and accidents, although
relevant differences were observed among the four con-
sidered cities. A higher mortality rate among IVDUs
compared with that of the general population was consis-
tently observed in all considered geographical cohorts16,17.
In a very recent 7-year survey from the US, active
drug use proved temporally linked to HIV disease pro-
gression and overall mortality17.
Our present study aims at:
i) investigating the past and present mortality trend
of a cohort of IVDUs based in Bologna, in an attempt to
identify its causes;
ii) investigating whether HIV infection plays any in-
fluence on the rate of mortality due to causes other than
AIDS;
iii) evaluating the AIDS-associated fatality rate among
subjects with missed or delayed HIV serodiagnosis, hen-
ce with a possible late diagnosis of the infection only at
an advanced stage of the condition.
Materials and Methods
Patients
An open cohort of 1,214 IVDUs has been assessed for
a number of epidemiological and clinical variables. The
people involved were mainly i.v. heroin addicts, and in-
cluded 916 males (75.5%) and 298 females, referring to a
specialized outpatient Centre for the treatment and pre-
vention of substance abuse of Bologna (Italy), from the
year 1977 up to November 1996. The great majority of
enrolled patients at the time of their first visit lived in
South-Western districts of the Bologna conurbation
(400,000 inhabitants in the city, half a million with the
suburbs). The place of birth is a missing datum for one
minor part of the people reached by our study; as to the
others, most of them were born within the Province of
Bologna and no one comes from abroad.
By matching anagraphical data with the registries of
the abode or birth municipalities, a retrospective re-
search focusing on whether subjects were still alive on
December 31, 2002, has been carried out.
In some cases, neither the year of birth nor the sub-
ject’s age were available due to patients’ refusal to pro-
vide their own personal data. Referring to population
registries allowed us to retrieve missing information re-
garding almost all individuals in our cohort: in 60 cases,
still assisted by our outpatient services, data are still
lacking, but for deceased patients figures were adjusted
when causes of death were researched.
HIV infection
At the time of patients’ first contact with our dedi-
cated outpatient centre, HIV testing and specific coun-
selling were always offered, but 355 subjects out 1,214
(29.2%) refused this examination. HIV serology became
recommended in late 1984, so that the first recognition of
a possible underlying HIV infection is related to the first
visit at our outpatient Centre, starting from 1984–1985.
IVDUs enrolled before 1985 had HIV testing performed
starting from this year either at the outpatient units, or
at one of the two Infectious Diseases Divisions of Bolo-
gna, or local prison facilities. At the time of their next
contact with the above-mentioned health care struc-
tures, HIV testing and specific counselling were always
offered. Data regarding HIV serostatus for IVDUs en-
rolled after 1985 dates back mainly to the time of first ac-
cess to IVDA outpatient Centres. Usually, the serocon-
version time for patients who were HIV-negative at their
first control is not definable, because of the limited avail-
ability of patients to be tested or to furnish results.
Statistical analysis
As to the calculations of person-years and rates, the
beginning of observation is identified with the year of the
first visit at our outpatient Centre for IVDUs. The first
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access date of 41 individuals is unknown; for each of
them, the enrollment was identified with the first date
available in his/her clinical records. The end of observa-
tion period was matched with that of death for deceased
patients, while it was fixed at December 31, 2002 for liv-
ing individuals; for two persons who were lost to fol-
low-up, the end-of-observation time is identified with
1997: the year of their last access to the Centre. The
cause of death of deceased subjects was drawn by local
registries, as expressed by the ICD-IX code18,19. Popula-
tion data were obtained from the official annual statisti-
cal update of Bologna; mortality figures were drawn by
public health notification registries.
Statistical analysis included specific mortality rates
per age, gender and HIV-status, and standardized mor-
tality rate (SMR)20, obtained by indirect standardization
performed on Bologna rates per each considered year.
Chi-square has been used for the analysis of frequency
distribution; Student’s t test and Analysis of variance
were employed to evaluate differences among mean val-
ues. The rates per HIV serostatus were calculated by at-
tributing the years of observation of each single subject
to his/her own category (HIV-positive, HIV-negative, HIV-
-unknown), without focusing on the time of seroconver-
sion (which was not always available). As a consequence,
not each person’s time of HIV-positive or HIV-negative
serology, but only the patient serostatus was considered.
The considered study time was analyzed according to
a wide range of variables, by dividing it into four differ-
ent periods, characterized by prominent epidemiologi-
cals, treatment, prognosis, type of medical assistance,
and outcome. The first period (years 1977–1983) encom-
passed the initial service offer, opposition and resistance
by patients, no deaths, and absence of HIV-AIDS cases;
the second period (1984–1990) was characterized by the
rapid spread of AIDS, spontaneous patient access, and
early HIV-associated deaths; during the third period
(year 1991–1996) the patient access remained sustained,
AIDS had the greatest fatality rate, and many deaths oc-
curred; the fourth period (years 1997–2002) was charac-
terized by the availability of highly active antiretroviral
therapy (HAART), followed by a sharp drop of AIDSmor-
tality. Our cohort was closed to enrollments at the end of
previous period.
Results
Series description – general features
Overall, 1,214 patients were considered: 916 males and
298 females. The distribution per age classes at the time
of enrollment is summarized in Table 1A, where also en-
rollment period is reported. The age of 60 subjects was not
available. Table 1B shows the subjects’ enrollment age in
different periods. One hundred and 10 IVDUs were en-
rolled from year 1977 to 1983. At the end of year 1990, pa-
tients still alive in our cohort were 607, and in the period
1991–1996 enrolled and alive patients became 1,174. The
characterizing features of the above- -mentioned time pe-
riods are recognizable in the cumulative Table 6.
Age and sex
Overall follow-up accounted for 10,030.50 person-
-years for male subjects, and 3,249.75 person-years for
females: cumulated follow-up accounted for 13,280.25
person-years. Mean age did not differ between enrolled
males and females, when considering both the entire fol-
low-up, and single time periods. A temporal trend to in-
creased patients’ age occurred through time: the differ-
ence among mean age at enrollment during different
time periods turned out to be significantly different (p<
.0001; Table 1B). The age at which each person started to
take up IVD was asked, but not provided for nearly one
half of involved subjects;.
HIV serostatus
When assessing HIV serostatus, IVDUs HIV-positive
were 426, and HIV-negative subjects were 433 (Table 2).
In particular, HIV infection was found in 297 men (32%
of males), and in 298 women (43% of females). Moreover,
among tested individuals, HIV-positive male patients ac-
counted for 46%, while females were 61%, leading to a
statistically different distribution (2=14,2667; p=
0.0002).
The record of HIV positive serostatus was documen-
ted in 8% of patients early HIV-negative; the great major-
ity of them was deducted from death certifications.
Analysis of deaths
Overall IVDUs subjects dead on December 31, 2002
were 271 (22.3% of all enrolled individuals): 211 males
(23% of enrolled males), and 60 females (20.1% of the fe-
male cohort). The mean patient age at the time of death
was comparable by gender: 33.2±6.6 years among males,
and 33.5±6.0 years among females (2=1,091, p=n.s.).
The overall 1.214 enrolled IVDUs accounted for
13,280.25 years-person (a mean of nearly 11 years per
patient), while the 271 deceased individuals contributed
for 1,258 years-person (an average of less than five years
per patient). Table 3 resumes all data concerning deaths,
classified per age group and sex, with person-years and
rates per 1000. The overall death distribution does not
show any significant difference between males and fe-
males. The time of initial i.v. drug addiction, when avail-
able, does not provide evidence of significant relation be-
tween age of start of IVDUs and eventual lethal outcome.
The cause of each single death has been retrieved for
267 of the 271 deceased patients (98.5%). No deaths were
registered in this cohort in the years preceding 1984. Fig-
ure 1 shows the different causes of death per year, in the
period 1984–2002. Overall AIDS-related deaths total 143
(52.8%), followed by those due to heroin overdose (60:
22.1%), liver cirrhosis (17: 6.3%), road accidents (20:
7.4%), suicide (8: 2.9%), homicide (3: 1.1%), infectious
endocarditis and other heart disorders (6: 2.2%), neo-
plasm (lung's or lymphoma, 5 deaths, 1.8%), and pneu-
monia (2: 0.7%). Three causes of death occurred only
once: wasting syndrome, bleeding endocranic aneurism,
and fire accident. The cause of death could not be found
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in four patients only. Table 4 reports the causes of death
stratified according to gender, with the associated rate
per 1000 person-years.
When examining deaths, according to whether they
are due to AIDS or not, it can be highlighted that 111 fa-
tal episodes non AIDS related occurred to males (41% of
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TABLE 1
BOLOGNA IVDU COHORT. CASE DISTRIBUTION ACCORDING TO SEX, ENROLLING PERIOD, AND AGE AT ENROLLMENT
(SECTION A); COMPARISON OF DIFFERENT PERIODS AND ENROLLMENT AGES (SECTION B)
Section A
Enrolling Period
Sex Age groups I II III All
Women 0–14 1 1 2
15–19 6 9 5 20
20–24 7 45 33 85
25–29 4 38 49 91
30–34 2 20 26 48
35–44 1 10 27 38
45–49 2 2
50–54 1 1
Nn 1 3 7 11
Total women 22 126 150 298
Mean age 22.71 26.06 29.01 27.29
Standard error 1.342 0.487 0.557 0.377
Men 0–14 2 2
15–19 21 18 10 49
20–24 41 130 95 266
25–29 16 125 143 284
30–34 6 55 97 158
35–44 1 22 67 90
45–49 2 10 12
50–54 1 3 4
>55 1 1 2
nn 2 19 28 49
Total men 88 374 454 916
Mean age 22.88 26.17 29.28 27.37
Standard error 0.609 0.287 0.324 0.219
Section B
Enrolling Period
Sex Age groups I II III All
Total 110 500 604 1214
Mean age 22.85 26.14 29.21 27.35
Standard deviation 5.7196 5.4080 6.6763
Standard error 0.553 0.247 0.280 0.189
95% confidence limits lower 21.7542 25.6562 28.6629
upper 23.9467 26.6283 29.7624
Median 22 25 28
Minimum 14 10 17
Maximum 56 53 62
Anova variation Deviance (SS) gf Variance (MS) p (F)
among periods 4837.661 2 2418.831
within periods 42735.203 1151 37.129
total 47572.864 1153 41.260 <0.001
overall men), while only 17 to females (28.3% of deceased
women). The general distribution of causes of death was
significantly different according to patient gender (p<
0.001): AIDS-related deaths proved significantly more
frequent among females, while overdose-related ones oc-
curred predominantly among males (2=11,042; p<
0.001). AIDS-related deaths have been compared with all
other cumulative causes of death, and disease caused
deaths with violence caused ones, in Table 5.
When analyzing the entire time span split into four
different periods (as mentioned above), not a single death
occurred in the period 1977–1983. Between 1984 and
1990, 40 deaths were registered among 459 enrolled sub-
jects (8.7%): 13 of them were attributed to AIDS, and 27
due to other causes. Between 1991 and 1996, of 1,174
IVDUs 172 deceased (14.6%): 109 dead because of AIDS,
and 63 due to all other possible causes. Between 1997
and 2002, among 1002 living subjects we observed 59
deaths (5,9%): 21 because of AIDS, and 38 due to all
other cumulative causes (Table 6).
Table 7 presents the mortality rate per 1000 person-
-years according to gender and grouped age of death, as well
considering HIV/AIDS, and all the other causes of death.
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TABLE 2





Negative 83 27.9% 350 38.2% 433
Positive 129 43.3% 297 32.4% 426
(not available) 86 28.9% 269 32.3% 355
Total 298 100% 916 100% 1214
TABLE 3
BOLOGNA IVDU COHORT. DISTRIBUTION OF DEATHS OVER THE FOUR GIVEN AGE GROUPS, CLASSIFIED BY GENDER.
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Fig. 1. Bologna IVDU cohort. Deaths per main causes during the whole time of observation. The cohort had no deaths until 1983.
When analyzing the separated time periods (as men-
tioned above), the mortality rate per 1000 patients-year
was 0/1000 (no deaths), 19.5/1000, 32.2/1000, and 10.2/
1000 respectively: in the overall period 1977–2002, the
mean mortality rate proved 20.4/1000. The highest fatal-
ity index was reached in the period 1991–1996, when it
accounted for 33.5/1000 among women, and 31.8/1000
among men.
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TABLE 4
BOLOGNA IVDU COHORT. ALL DEATHS OCCURRED IN OUR COHORT ARE REGISTERED ACCORDING TO THEIR RECOGNIZED
CAUSES. BOTH ABSOLUTE FIGURES AND MORTALITY RATE PER 1,000 PATIENTS-YEARS (P-YS) ARE SHOWN
Sex Females Males Total
Cause of death Deceased Rate/1000 p-ys Deceased Rate/1000 p-ys Deceased Rate/1000 p-ys
AIDS 43 13.231 100 9.970 143 10.768
Overdose 6 1.846 54 5.384 60 4.518
Hepatitis, cyrrhosis 3 0.923 14 1.396 17 1.280
Heart diseases 0 6 0.598 6 0.452
Road accidents 5 1.539 15 1.495 20 1.506
Suicide 1 0.308 7 0.698 8 0.602
Neoplasm 1 0.308 4 0.399 5 0.377
Respiratory pathologies 0 2 0.199 2 0.150
Undefined cause 0 2 0.199 2 0.150
Other violent causes 0 4 0.399 4 0.301
Unknown causes 1 0.308 3 0.299 4 0.301
Total 60 18.463 211 21.036 271 20.406
TABLE 5
BOLOGNA IVDU COHORT. DEATH DISTRIBUTION ACCORDING TO SETS OF DEATH CAUSES: AIDS, NON-AIDS,
AND DISEASE/VIOLENT DEATH
Sex Females Males Total
Deceased Rate/1000 p-ys Deceased Rate/1000 p-ys Deceased Rate/1000 p-ys
AIDS 43 13.231 100 9.970 143 10.768
Non-AIDS 16 4.923 108 10.767 128 9.337
Unknown 1 0.308 3 0.299 4 0.301
Total 60 18.463 211 21.036 271 20.406
Diseases 47 14.463 126 12.562 173 13.027
Violent causes 12 3.693 80 7.976 92 6.928
Unknown or undefined causes 1 0.308 5 0.499 6 0.452
Total 60 18.463 211 21.036 271 20.406
TABLE 6
BOLOGNA IVDU COHORT. DYNAMIC TRENDS OBSERVED IN OUR PATIENTS: ENROLLMENTS AND DEATHS OCCURRED DURING
THE FOUR GIVEN TIME PERIODS
Periods I II III IV Total
Years 1977–1983 1984–1990 1991–1996 1997–2002 1977–2002
Survivors at prior time interval – 110 570 1002
Newly enrolled subjects 110 500 604 0 1214
IVDUs alive in the period 110 610 1174 1002
IVDUs deceased in the relevant period 0 40 172 59 271
Fatality rate (%) in the relevant period 0% 6.6% 14.6% 5.9% 22.3%
Subjects lost at follow-up 0 0 0 2 2
Subjects alive at the end of follow-up 110 570 1002 941 941
Figure 2 shows the smoothed temporal trend of stan-
dardized mortality rate (SMR) for all causes, 1986 to
2002 (upper line). The lower line shows the SMR calcu-
lated without considering AIDS-associated deaths, so
that the area between the two curves represents the ab-
solute contribution of AIDS to excess mortality during
the relevant period. The decrease of deaths due to other
causes shows a drop paralleling that of AIDS-related fa-
tality events, but excess mortality remains higher than
the values observed in the pre-AIDS era.
When considering our series according to first HIV
serostatus, we obtained a rate of 37,00/1000 for HIV-in-
fected patients, compared with 17,00/1000 for non-HIV-
-infected IVDUs, and 7,85//1000 for individuals with un-
determined HIV serostatus. In the whole time period,
the mortality index was higher for male HIV- positive pa-
tients compared with HIV-positive females, but women
aged 25–44 years, as subgroup, had the greatest risk of
death for AIDS. When excluding AIDS, all other causes of
death largely predominated among males, especially for
people aged 25–44 years. In more detail, the highest risk
of death was found in the group aged 25–34 years, while
only a few deaths were observed Table 9 presents mortal-
ity rate analyzed according to HIV serostatus and subdi-
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Fig. 2. Bologna IVDU cohort. Mortality trend from 1996 to 2001. Yearly SMR for all death causes. Indirect standardization based on Bolo-
gna population rates for each year (upper line), smoothed using weighted adjacent year values. Lower line shows the contribution to
SMR of death causes other than AIDS; the area comprised between the two slopes identifies AIDS contribution to deaths.
TABLE 7
BOLOGNA IVDU COHORT. DEATH DISTRIBUTION PER CAUSES (AIDS/NON-AIDS), AGE GROUPS, AND SEX
Sex










Females <25 1 2.99 0 0.00 1 2.99
25–34 8 5.03 28 17.61 1 37 24.53
35–44 5 4.92 14 13.78 19 15.75
>44 2 10.23 1 5.12 3 20.46
Total 16 4.92 43 13.23 1 60 18.46
Males <25 11 11.66 1 1.06 12 11.66
25–34 60 12.37 61 12.57 2 123 26.80
35–44 30 9.65 32 10.29 1 63 18.33
>44 7 11.51 6 9.87 13 21.38





124 9.34 143 10.77 4 271 20.41
vided following the four more frequent causes of death;
the »miscellaneous« patient group includes the four
IVDUs whose death cause is unknown.before 25 years of
age, and after the age of 45 (Tables 7 and 8).
Table 9 presents mortality rate analyzed according to
HIV serostatus and subdivided following the four more
frequent causes of death: the »miscellaneous« patient
group includes the four IVDUs whose death disease in
unknown. Among the 143 patients deceased because of
AIDS, we registered 32 IVDUs who were HIV-negative
upon enrollment, and 3 subjects who did not undergo
HIV testing, but who became known as HIV-infected
when death cause was obtained. Two more HIV-un-
known subjects, who resulted HIV-positive at death, died
because of liver diseases.
Among IVDUs who deceased because of overdose,
33.3% had HIV infection, 43.3% was HIV-negative (not
statistically significant difference), while the HIV sero-
status of the remaining 23.3% was not ascertained. At
death, the prevalence of HIV infection is significantly
higher among females (81.7%) than among males (68.7%;
p<0.001).Mortality rates per 1000 person-years for HIV-
-infected, HIV-negative, HIV-unknown patients, strati-
fied according to gender, are shown in Table 8. Among
271 deceased IVDUs, those infected with HIV were 194
(71.6%), including 145 males and 49 females. HIV-nega-
tive IVDUs were 46 (16.9%), including 41 males and five
females; deceased IVDUs with unknown HIV serostatus
were 31 (11.4%), including 25 males and six females. The
patients, whose serostatus was negative or unknown,
and who resulted HIV infected from death cause, are 37.
As already mentioned, 35 of them died because of AIDS;
as well two HIV-unknown, proved HIV-positive at death,
died because of liver diseases. At the time of death, this
last patient group was aged 25 to 34 years in 66% of
cases, while the remaining IVDUs of this subgroup were
aged 35–44 years. All these patients died between 1991
and 1997.
Discussion and Conclusion
In a 25-year-long observation study, the wide time
span of our follow-up allows us to assess the mortality
trend along well distinguished periods: the pre-AIDS era,
the HIV pandemic era, and the HAART era (with the in-
troduction and consolidation of HAART as the standard
of antiretroviral care for HIV disease).
Several Authors point out that, if the availability of
potent HAART regimens has improved the prognosis of
HIV disease since end-1996 or early 1997, this effect ap-
plies only to those IVDU who have undergone serodia-
gnosis turning out positive to the test, then have ac-
cepted antiretroviral treatment, and have followed it
with satisfactory adherence levels17,21–25.
Our data show that an initally slow, but later progres-
sive increase in the number of deaths has taken place
since 1984 (the year when the first death of our cohort
was registered). After the first AIDS-related death was
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TABLE 8
BOLOGNA IVDU COHORT. MORTALITY RATE PER 1,000 PERSONS-YEARS ANALYZED ACCORDING TO GENDER, SUBDIVIDED INTO


















Total 37.00 17.00 7.85 20.41
TABLE 9
BOLOGNA IVDU COHORT. MORTALITY RATE ACCORDING TO HIV SEROSTATIS AND MOST RELEVANT CAUSES OF DEATH.
»MISCELLANEOUS« REFERS TO THE LESS FREQUENT CAUSES CONSIDERED AS A WHOLE. HIV-INFECTED SUBJECTS INCLUDE
PATIENTS WHOSE HIV SEROSTATUS WAS IDENTIFIED ONLY FROM THEIR DEATH CAUSE CERTIFICATE


















































Total 194 146.1 46 34.6 31 23.3
(*) The subjects known as HIV-negative and the subjects with unknown HIV serostatus who died because of AIDS are reported in this
group, as mentioned in the text.
reported, in 1986, the increase in the mortality rate of
our cohort became increasingly important until 1994,
with the last peak observed in the year 1996 (immedi-
ately before the introduction of HAART). Since 1997,
with the implementation of potent HAART regimens, a
dramatic drop of AIDS-associated deaths has been ob-
served in our cohort of IVDUs. In more details, excep-
tionally high standardized mortality rates (SMR) were
reached between 1988–1997, followed by a significant re-
duction from 1998. A limited increase observed in 2000,
was however not confirmed over the following two years.
As to the causes of death in our extensive observational
cohort, death due to AIDS and drug overdose were re-
markably predominant among males, applying to HIV
positive, HIV negative and HIV unknowkn alike.
Previous experiences carried out by us12, proved that
overdose-associated deaths in Bologna since 1994 have
accounted for a steadily increasing fraction of the overall
Emilia-Romagna regional reported cases. Based on all
the above-mentioned comprehensive data, we don’t think
we can read a decrease in the risk of death from heroin
overdose in our cohort until 1997, while in Italy some cu-
mulative data have shown a progressive reduction of this
cause of death already since 199613. We would like to
stress that death in the female component of our cohort
is largely related to AIDS-associated causes, all other
causes showing a lower frequency among women. For a
correct interpretation of these data, it is necessary to
consider the higher prevalence of HIV serostatus among
women with respect to men, in our cohort.
Since 1998, in our observational study, we witnessed a
significant reduction of both AIDS-related deaths (still
quite high in 1997), and overdose-caused deaths, which
dropped to a half in 1998 compared to 1996 and 1997.
Such a notable reduction in frequency could be related to
a concurrent increase of substitutive methadone treat-
ment, carried out in most of IVDUs outpatient services of
Bologna over the same period of time. In the Emilia-
-Romagna region, the implementation of the so-called
»damage reduction strategy« had already significantly
contributed to foster a decrease in overdose-related
deaths in such cities as Modena or Ferrara, where metha-
done treatment had been massively introduced among
IVDUs since early 90s15. Since 1997 the global mortality
trend for all non-AIDS-related deaths has paralleled the
decrease in AIDS-associated fatalities. A very recent
study from Baltimore (USA) longitudinally followed i.v.
drug abusers with a concurrent HIV infection since 1998
(when HAART was already available since three years.
The authors observed that active drug use was tempo-
rally linked to HIV disease progression and overall mor-
tality17.
Over two thirds of all deceased subjects in our cohort
were HIV-infected. Nearly half of all deaths were related
to AIDS. Awareness of the infection can be regarded both
as a possible concurrent reason for adopting risky behav-
iour or even for suicide (from overdose to car accidents,
suffered or committed aggressions, reported self-dam-
age), and as a cause of increased caution which can lead
to approach and trust in outpatient health care services.
In our series, the progressively increasing patient’s age
at enrollment observed throughout the study period, is
linked to the ageing of IVDU population who refer to
dedicated outpatient services. These data are not related
with any evidence that proportionally younger patient
population is at modified risk of IVDU.
During the whole analyzed period, the mortality rate
for all causes is higher for male HIV-infected IVDUs than
for female HIV-infected IVDUs, but women aged 25 to 44
years represented the subgroup at higher risk of AIDS-
-related death, as confirmed by a very recent study from
Canada24. When excluding AIDS, all diseases involved as
a cause of death in our cohort were predominantly pres-
ent in the male component of our patients group, notably
in the age interval ranging from 25 to 44 years. In more
details the highest mortality risk applies to the 25–34 age
group, while it is at its lowest before 25, and after 45
years of age.
Should HAARTmaintain its remarkable effectiveness
in future years, a further increase of life expectancy of
HIV-infected subjects could be foreseen17,24–26. This fa-
vorable condition may induce the IVDU population to re-
fer to dedicated outpatient centres, and adhere to both
HAART and substitutive pharmacological strategies
aimed at »drug damage containment«, and may therefore
benefit from a further reduction of overdose-related
deaths. On the other hand, we cannot exclude that a pro-
gressively lowering HIV morbidity may allow a long-
-term increase of incidence of chronic concurrent dis-
eases commonly affecting the same IVDU population, as
causes of mortality (i.e. decompensated liver cirrhosis,
cancer)6. Moreover, we also cannot exclude that part of
these patients will continue and/or resume the use of
drugs while undergoing treatment for HIV disease, hen-
ce remaining prone to incur in lethal overdose episodes.
In conclusion, we would strongly recommend repea-
ted HIV serology for all IVDUs and persons adopting
HIV-risky sexual practices, who have undergone previ-
ous HIV tests with negative results. This is meant to
avoid that patients regarded as HIV negative, who then
got infected while carrying on their risky practices
through the exchange of syringes or through sexual con-
tacts, may end up with their infection not being diag-
nosed until their HIV infection progresses into advanced
clinical signs and symptoms, related to a more severe im-
munological and neurological deterioration, more un-
likely to be treated successfully. The favorable perspec-
tive offered by the large-scale availability of multiple
HAART combinations for HIV-infected IVDUs makes it
absolutely necessary nowadays to apply a more strict and
effective epidemiological monitoring of the population
at-risk, especially of IVDUs27. It is in fact worth remind-
ing that in Italy there is wide recorded evidence of gen-
eral lack of awareness of the HIV serostatus of current
and past sexual partners in many patients who have been
later tested and resulted positive for HIV and/or AIDS.
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SMANJENJE SMRTNOSTI U SKUPINI OVISNIKA O DROGAMA NA PODRU^JU
GRADA BOLONJE, ITALIJA
S A @ E T A K
Cilj ovog istra`ivanja je ocijeniti trenutni trend smrtnosti u skupini intravenoznih ovisnika o drogama (eng. intra
venous drug users, IVDU) pra}enih u gradu sjeverne Italije, Bolonji i procijeniti povezanost s HIV infekcijama i AIDS-om,
te dostupnost u~inkovite antiretroviralne terapije. 1214 IVDUa (uglavnom ovisnika o heroinu), 916 mu{karaca i 298
`ena, koji su dolazili u ambulante radi lije~enja i prevencije ovisnosti u razdoblju od 1977. godine i studenog 1996.
godine, ili su uklju~eni u na{u promatranu skupinu te je njihov vitalni status bio prou~avan sve do 31. 12 2002. godine.
Velika ve}ina ispitanika uklju~enih u istra`ivanje bili su ro|eni na podru~ju grada Bolonje i njegovoj okolici, imigranti
izvan podru~ja Europe nisi bili uklju~eni. Tijekom perioda promatranja 271 IVDU (22.3%) je umro, 211 mu{karaca
(23.0%) i 60 `ena (20.1%). Niti jedan smrtni slu~aj nije zabilje`en prije 1984. godine. Glavni uzroci smrti su slijede}i:
AIDS (52.8% slu~ajeva), predoziranje heroinom (22.1%), uli~ne nesre}e (7.4%), ciroza jetre (6.3%), i samoubojstvo (2.9%).
Najve}i sveukupni broj smrtnih slu~ajeva primije}en je izme|u 1991. i 1996. godine. Gruba stopa smrtnosti uzrokovana
AIDS-om bila je 10.0 na1000 za mu{karce i 13.2 na 1000 za `ene, a utvr|ena stopa smrtnosti iz drugih razloga 11.1/
1000 me|u mu{karcima i 5.2/1000 me|u `enama. Posljednjih je godina zabilje`en nagli pad u broju smrtnih slu~ajeva
povezanih s AIDS-om kod IVDUa, {to se pripisuje u~inkovitim antiretroviralnim re`imima, iako je sveukupna stopa
smrtnosti i dalje ostala zna~ajna.
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